RT Journal Article
SR Electronic
T1 High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes
JF ERJ Open Research
JO erjor
FD European Respiratory Society
SP 00110-2016
DO 10.1183/23120541.00110-2016
VO 3
IS 2
A1 Rieneke van de Ven
A1 Anna-Larissa N. Niemeijer
A1 Anita G.M. Stam
A1 Sayed M.S. Hashemi
A1 Christian G. Slockers
A1 Johannes M. Daniels
A1 Erik Thunnissen
A1 Egbert F. Smit
A1 Tanja D. de Gruijl
A1 Adrianus J. de Langen
YR 2017
UL http://openres.ersjournals.com/content/3/2/00110-2016.abstract
AB The treatment of advanced nonsmall cell lung cancer (NSCLC) with PD-1/PD-L1 immune checkpoint inhibitors has improved clinical outcome for a proportion of patients. The current challenge is to find better biomarkers than PD-L1 immunohistochemistry (IHC) that will identify patients likely to benefit from this therapy. In this exploratory study we assessed the differences in T-cell subsets and PD-1 expression levels on T-cells in tumour-draining lymph nodes (TDLNs) and peripheral blood mononuclear cells (PBMCs).To evaluate this, flow cytometric analyses were performed on endobronchial ultrasound-guided (EBUS) fine-needle aspirates (FNA) from TDLNs of patients with NSCLC, and the results were compared to paired PBMC samples. For a select number of patients, we were also able to obtain cells from a non-TDLN (NTDLN) sample.Our data show that the frequency of PD-1+ CD4+ and CD8+ T-cells, as well as the PD-1 expression level on activated regulatory T (aTreg) and CD4+ and CD8+ T-cells, are higher in TDLNs than in PBMCs and, in a small sub-analysis, NTDLNs.These elevated PD-1 expression levels in TDLNs may reflect tumour-specific T-cell priming and conditioning, and may serve as a predictive or early-response biomarker during PD-1 checkpoint blockade.PD-1 in NSCLC tumour-draining lymph nodes as a potential biomarker http://ow.ly/QedU30bqJ6d